Pulse Biosciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $350.0K | $0 | $0 | $700.0K | $1.4M | $0 | — |
| Cost of Revenue | — | $539.0K | $0 | $0 | $11.9M | $2.0M | $0 | $600.0K |
| Gross Profit | — | $-189.0K | $0 | $0 | $-11.2M | $-550.0K | $0 | — |
| Gross Margin | — | -54.0% | — | — | -1,606.3% | -38.8% | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $44.7M | $32.3M | $27.8M | $20.8M | $28.6M | $26.4M | $25.0M |
| SG&A Expense | — | $32.0M | $23.9M | $15.8M | $14.0M | $19.1M | $16.3M | $17.1M |
| Operating Income | — | $-76.9M | $-56.3M | $-43.6M | $-58.1M | $-63.0M | $-50.0M | $-48.0M |
| Operating Margin | — | -21,982.6% | — | — | -8,293.9% | -4,443.9% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $72.8M | $53.6M | $-42.2M | $-58.5M | $-63.7M | $-49.9M | $-47.0M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | — | $-72.8M | $-53.6M | $-42.2M | $-58.5M | $-63.7M | $-49.9M | $-47.0M |
| Net Margin | — | -20,794.6% | — | — | -8,357.9% | -4,489.4% | — | — |
| EPS (Basic) | — | $-1.08 | $-0.92 | $-0.85 | $-1.72 | $-2.28 | $-2.14 | $-2.26 |
| EPS (Diluted) | — | — | — | — | — | $-2.28 | $-2.14 | $-2.26 |
| Shares Outstanding (Basic) | 68.2M | 67.4M | 58.4M | 49.7M | 33.9M | 28.0M | 23.2M | 20.8M |
| Shares Outstanding (Diluted) | 68.2M | 67.4M | 58.4M | 49.7M | 33.9M | 28.0M | 23.2M | 20.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |